BRIDGEBIO PHARMA, INC.

Lobbying for BRIDGEBIO PHARMA, INC. · Biotech company

Amended

The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Jul 17, 2026.

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$270,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

HR 1262
Mikaela Naylon Give Kids a Chance Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 1

Pharmacy

Give Kids a Chance Act of 2025 - H.R. 1262; S 932 General issues and provisions related to PBM Reform ORPHAN Cures Act - included in H.R. 1 - One Big Beautiful Bill Act Orphan drug policies

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.